

The 2025 Learning Journey in Cardiovascular Disease & Hypertension: A Patient-Centred Educational Experience

LIVE WEBINAR


Heart rate, hypertension and high cardiovascular risk:
the key role of multidisciplinary approach in patients'
management

30 May 2025

From 13:30 to 14:30 CEST

For website page
CLICK HERE





OVERVIEW

The latest European guidelines about diagnosis and management of hypertension introduced several topics of interest regarding risk stratification, and multidisciplinary approach. Adherence to treatment is still a key issue affecting clinical outcomes, and many strategies are suggested to improve patients' compliance to therapies.

In addition, given the always growing percentage of hypertensive patients with cardiovascular (CV) diseases, beta-blockers (BB) and their up-titration to maximum tolerated dose represents a clinical task which strongly needs to be correctly addressed.

LEARNING OBJECTIVES

- Recognize the need for CV risk stratification in every hypertensive patient
- Understand the relevance of a comprehensive multidisciplinary approach to hypertensive patient
- Assess current indications to beta-blockers, and correctly identify the need for up-titration

TARGET AUDIENCE

Cardiologists, endocrinologists, gynecologists, internal medicine specialists, general practitioners


LANGUAGE

English with simultaneous translation into Russian and Spanish

**For registration
CLICK HERE**



REGISTRATION IS FREE
OF CHARGE



CONTINUING MEDICAL EDUCATION

The Live Webinar: **Heart rate, hypertension and high cardiovascular risk: the key role of multidisciplinary approach in patients' management, Rome, Italy, Italy 30/05/2025 - 30/05/2025**, has been accredited by the **European Accreditation Council for Continuing Medical Education (EACCME®)** with **1.0 European CME credits (ECMEC®s)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity."

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits TM. Information on the process to convert EACCME® credit to AMA credit can be found at:

<https://edhub.ama-assn.org/pages/applications>

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.



CME PROVIDER

Scientific Seminars International Foundation

Senior Program Manager: Annamaria Nestico

annamaria.nestico@scientificseminars.com

education@scientificseminars.com

MEDICAL ADVISOR


Emiliano Angeloni

Cardiovascular Pathophysiology and Imaging

Heart and Great Vessels Surgery

Valle Giulia Clinic

Rome, Italy



FACULTY

Emiliano Angeloni


Cardiovascular Pathophysiology and Imaging
Heart and Great Vessels Surgery
Valle Giulia Clinic
Rome, Italy

Lucas Lauder

Clinic of Cardiology
University Heart Center
University Hospital Basel
Basel, Switzerland

Konstantinos Tsioufis

1st Department of Cardiology
National and Kapodistrian University of Athens
Hippokration Hospital
Athens, Greece



SCIENTIFIC PROGRAM


HEART RATE, HYPERTENSION AND HIGH CARDIOVASCULAR RISK: THE KEY ROLE OF MULTIDISCIPLINARY APPROACH IN PATIENTS' MANAGEMENT

FRIDAY, 30 MAY 2025
From 13:30 to 14:30 CEST

Chair:		E. Angeloni (Italy)
13.30		Welcome and Introduction E. Angeloni (Italy)
13.35		L1 Hypertension Guidelines overview E. Angeloni (Italy)
13.45		L2 Multidisciplinary approach to hypertension: to implement lifestyle modification and improve adherence to treatment K. Tsioufis (Greece)
14.00		L3 Beta blockers: indications and up titration L. Lauder (Switzerland)
14.20		Q&A, General discussion with participants
14.30		Concluding remarks and end of the live webinar

LEGEND

 Lecture  Q&A General discussion with participants  Concluding remarks



FACULTY DISCLOSURES

Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter).

We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Emiliano Angeloni


Declared no potential conflict of interest

Lucas Lauder

Declared receipt of grants/research supports and/or honoraria or consultation fees from AstraZeneca, Medtronic, Pfizer, Recor Medical

Konstantinos Tsioufis

Declared no potential conflict of interest



CHAIRMAN AND FACULTY MEMBER


EMILIANO ANGELONI



Emiliano Angeloni is a Medical and Philosophical Doctor, and II-tier habilitated Professor with wide expertise in the field of cardiovascular diseases.

Beyond his working experience at Royal Brompton Hospital of London (UK) and teaching experience at Sapienza, University of Rome; among the last 15 years he has published over 40 papers on international indexed journals (such as European Heart Journal, JACC, and Circulation), and presented over 60 scientific communications in several international meetings (such as the ESC, AHA, ACC, EACTS, AATS, and STS annual congresses).

He has also been repeatedly invited to contribute in international events and media communications (such as ESC TV, EACTS Daily News, and AATS Symposiums).




FACULTY

LUCAS LAUDER



Dr. Lucas Lauder is a consultant at the Department of Cardiology at the University Hospital Basel (USB). His main clinical focus is preventive medicine and the treatment of heart failure. His research interests particularly include cardiorenal interaction, adherence to pharmacological therapy, autonomic modulation, and interventional treatment options for cardiovascular diseases. Dr. Lauder is a co-author of the ESC Guidelines on Arterial Hypertension (2024), a core member of the German Cardiac Society working group on arterial Hypertension, and co-chair of the European Society of Hypertension Working Group on Device-based Treatment of Hypertension.



FACULTY

KONSTANTINOS TSIOUFIS




Dr. Tsioufis is Professor of Cardiology in the National and Kapodistrian University of Athens and he is Chief of the First Department of Cardiology, Hippokration Hospital, Athens, Greece.

Clinical Training in Interventional Cardiology and Hypertension at the University of Athens, Greece and later at the Veterans Affairs Medical Center, Georgetown University, Washington DC, USA.

Areas of expertise: interventional cardiology (PCI, coronary and peripheral arteries, stenting renal arteries, TAVI, closure of PFO/ASD, mitral clip, renal denervation)

Publications: He has published widely on hypertensive disease, cardiorenal disease, atherosclerotic cardiovascular disease and interventional cardiology and he is involved in major clinical trials regarding novel interventional therapies of hypertension and particularly renal denervation. He has more than 600 publications in peer-reviewed Journals (H-index> 60). He has contributed with more than 25 Chapters in Books.

Academic positions: He is Member of the Editorial Board and Reviewer in major Cardiology, Hypertension and Critical Care Journals. President of European Society of Hypertension (2017-2019) President of Hellenic Society of Cardiology (2016-2018)



All Scientific Seminars International Foundation programs are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Scientific Seminars International Foundation. This independent educational program is made possible thanks to an educational grant received from Merck Healthcare KGaA Darmstadt Germany.

**For registration
CLICK HERE**



REGISTRATION IS FREE
OF CHARGE



Scientific Seminars International Foundation

Via di Porta Pinciana, 6 - 00187 Roma

www.scientificseminars.com

